Please assess the completion status of the following clinical trial:

Trial Title: Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged ≥18 years and ≤ 60 years.~* Absolute neutrophil count (ANC) of \>1000/mm3 for African black population and ≥ 1600/mm3 for all other races.~* For Cohort 2: HIV-negative~* For Cohorts 1 and 3: HIV-1 positive; CD4 count of at least 300/mm3; HIV-1 RNA copies (viral load) \>10 000 copies/mL serum; and current physical health stable and not requiring antiretroviral treatment~* For Cohorts 1 and 3: Chest x-ray showing absence of active infectious diseases (such as tuberculosis, viral or atypical bacteria or parasitic infection).~Exclusion Criteria:~* Presence of any severe concomitant disease.~* History of or current, recurrent or recent (4 weeks) febrile disease.~* History of opportunistic infections, neoplasm or AIDS-defining conditions.~* Inability to discontinue any medication from screening onwards, or for at least 2 weeks before the first admission; in particular any antiviral or therapy with immunosuppressive activity.~* Significant liver impairment: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 2.5 times the upper normal limit.~* Significant kidney impairment: serum creatinine ≥ two times the upper normal limit.~* Any concomitant disorder or resultant therapy likely to have interfered with subject compliance or with study procedures.~* Known hypersensitivity to any of the test materials or related compounds.~* Positive test for Hepatitis B and/or C antibodies.~* A history of multiple and/or severe allergies to drugs or foods or a history of anaphylactic reactions.~* History of seizures or epilepsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
- Cohort 2 (Type: EXPERIMENTAL): Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
- Cohort 3 (Type: EXPERIMENTAL): Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).